Khartis raises $50M Series B for oral immunology medicines

Khartis Therapeutics, an oral small-molecule medicines developer, emerged from stealth with $95 million, including a new $50 million Series B.

Why it matters: Biotechs are increasingly trying to offer alternatives to established injectable biologics.